左乙拉西坦常规预防对CD19 CAR-T治疗LBCL无获益:一项多中心倾向评分匹配研究
该多中心倾向评分匹配研究纳入254例接受抗CD19 CAR-T治疗的LBCL患者,按1:1比较左乙拉西坦预防组与未预防组。结果显示两组任何级别ICANS发生率无显著差异(LVT未用组32.3% vs LVT预防组37.1%,P=.29),严重ICANS亦无显著差异;LVT预防组早期ICAHT发生率更高(2-4级37.3% vs 63.9%,P<.001)。总生存与无进展生存两组无显著差异。
要点
- 左乙拉西坦预防未降低任何级别ICANS发生率(32.3% vs 37.1%,P=.29)。
- 左乙拉西坦预防组2-4级早期ICAHT发生率更高(37.3% vs 63.9%,P<.001)。
- 两组总生存与无进展生存无显著差异(P=.337和.670)。
核心结论
- 常规使用左乙拉西坦预防CAR-T治疗中的ICANS无效,需进一步研究以明确其在特定人群或ICANS治疗后的作用。
研究设计与样本
- 多中心倾向评分匹配队列研究,纳入254例接受抗CD19 CAR-T治疗的LBCL患者,按1:1匹配比较左乙拉西坦预防组与未预防组。
主要发现
- 任何级别ICANS发生率在LVT未用组为32.3%,LVT预防组为37.1%(P=.29),无显著差异。
- 2-4级ICANS发生率在LVT未用组为15.1%,LVT预防组为16.1%(P=.80);3-4级ICANS发生率分别为7.9%和9.7%(P=.71),均无显著差异。
- 2-4级早期ICAHT发生率在LVT未用组为37.3%,LVT预防组为63.9%(P<.001),LVT预防组更高。
- 总生存和无进展生存两组无显著差异(P=.337和.670),非复发死亡率相当(P=.77)。
临床怎么用
- 作者认为常规使用左乙拉西坦预防CAR-T治疗中的ICANS无效,需进一步研究以明确其在特定人群或ICANS治疗后的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to evaluate the impact of levetiracetam (LVT) prophylaxis on the incidence and severity of immune effector cell-associated neurotoxicity syndrome (ICANS) in patients undergoing anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for LBCL (large B-cell lymphoma). A propensity score-matched cohort of 254 patients was analyzed, comparing those receiving LVT prophylaxis (LTV-yes) with those not receiving it (LTV-no), in a 1:1 ratio. The results showed no significant difference in the occurrence of ICANS of any grade between the 2 groups (32.3% in LVT-no vs 37.1% in LVT-yes; P = .29), or in severe ICANS (grades 2-4, 15.1% vs 16.1% [P = .80]; grade 3-4, 7.9% vs 9.7% [P = .71]). The use of LVT was associated with a higher incidence of early immune effector cell-associated hematotoxicity (ICAHT), with grade 2 to 4 ICAHT occurring in 37.3% vs 63.9% (P < .001) of patients in the LVT-no and LVT-yes groups, respectively. Overall survival and progression-free survival did not differ significantly between the 2 groups (P = .337 and .670). Nonrelapse mortality rates were comparable (P = .77). These findings suggest that routine use of LVT as prophylaxis for ICANS in CAR-T therapy is not effective, and further research is needed to refine its role in selected populations or after ICANS treatment.
引用
- Galli E, Di Blasi R, Di Rocco A, et al. Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study. Blood Adv. 2025. PMID: 40779573. doi:10.1182/bloodadvances.2025017378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。